| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 1915902 | Journal of the Neurological Sciences | 2007 | 4 Pages |
Abstract
Bortezomib, a proteasome inhibitor used in the treatment of multiple myeloma, is known to induce an axonal, dose-dependent neuropathy clinically characterized by pain, paresthesias, burning dysesthesias and numbness.In this study, we describe a patient treated with high-dose bortezomib whose main clinical feature was severe sensory ataxia. Electrodiagnostic studies showed, other than axonal changes, myelin involvement.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Ageing
Authors
Massimiliano Filosto, Giuseppe Rossi, Anna Maria Pelizzari, Serena Buzio, Marta Tentorio, Laura Broglio, Michelangelo Mancuso, Marianna Rinaldi, Mauro Scarpelli, Alessandro Padovani,